Missing Links? Citation Matrix Graphs Glossary  HistCite Guide  About
Wed Oct 27 15:04:09 2004

Papers with "thalidomide" in the title, 1980-2004

Nodes: 1975, Authors: 5409, Journals: 512, Outer References: 13295, Words: 3300
Collection span: 1980 - 2004
View: Overview. Sorted by year, source, volume, issue, page.
Page 5:  1  2  3  4  5  6  7
#LCRNCRNodes / Date / Journal / AuthorsLCSGCS
12015211201 2001 HAEMATOLOGICA 86(4):404-408
Hus M; Dmoszynska A; Soroka-Wojtaszko M; Jawniak D; Legiec W; Ciepnuch H; Hellmann A; Wolska-Smolen T; Skotnicki A; Manko J; Polish Multiple Myeloma Study Grp
Thalidomide treatment of resistant or relapsed multiple myeloma patients
2335
120217331202 2001 HAEMATOLOGICA 86(4):409-413
Tosi P; Ronconi S; Zamagni E; Cellini C; Grafone T; Cangini D; Pileri SA; Baccarani M; Tura S; Cavo M
Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation
1321
1203001203 2001 HAEMATOLOGICA 86(4):448-448
Zappasodi P; Lorenzi A; Corso A
Thalidomide in refractory myeloma patients: early changes in bone marrow cellularity
11
1204291204 2001 HAEMATOLOGICA 86(7):772-773
Pozzato G; Zorat F; Nascimben F; Comar C; Kikic F; Festini G
Thalidomide therapy in compensated and decompensated myelofibrosis with myeloid metaplasia
711
12058101205 2001 HAEMATOLOGICA 86(10):1108-1109
Camba L; Peccatori J; Pescarollo A; Tresoldi M; Corradini P; Bregni M
Thalidomide and thrombosis in patients with multiple myeloma
1112
12065201206 2001 HAUTARZT 52:962-965
Hoch O; Muller S; Buttner G; Mensing H
Thalidomide in the treatment of cutaneous and systemic sarcoidosis
35
12073151207 2001 HAUTARZT 52:966-969
Petering H; Kiehl P; Vogelbruch M; Sticht-Groh V; Kapp A; Werfel T
Chemotherapy-induced erythema nodosum leprosum: successful treatment with thalidomide
00
120848681208 2001 HAUTARZT 52(8):726-733
Kuhn A; Hefter H; Ruzicka T; Lehmann P
Rediscovery of thalidomide. Successful treatment of discoid lupus erythematosus
00
1209001209 2001 HEPATOLOGY 34(4):279A-279A
Muriel P; Fernandez-Martinez E; Perez-Alvarez VM; Morales-Rios MS
A thalidomide analog with hepatoprotective and antifibrotic properties in biliary obstruction-induced cirrhosis in the rat.
00
1210001210 2001 HEPATOLOGY 34(4):516A-516A
Muriel P; Ponce S; Garcia JC
Thalidomide partially prevents CCl4-induced liver cirrhosis.
00
#LCRNCRNodes / Date / Journal / AuthorsLCSGCS
1211001211 2001 HEPATOLOGY 34(4):517A-517A
Muriel P; Garcia JC; Ponce S; Perez-Alvarez VM; Fernandez-Martinez E; Morales-Rios MS
Synthesis and pharmacological evaluation of a thalidomide analog, the 3-phthalimido-3-(3,4-dimethoxyphenyl)propanoic acid in liver cirrhosis induced by bile duct ligation in the rat.
00
121218361212 2001 INFLAMMATION 25(2):91-96
Belo AV; Ferreira MAND; Bosco AA; Machado RDP; Andrade SP
Differential effects of thalidomide on angiogenesis and tumor growth in mice
02
121313231213 2001 INTERNATIONAL IMMUNOPHARMACOLOGY 1(1):49-61
Rowland TL; McHugh SM; Deighton J; Ewan PW; Dearman RJ; Kimber I
Differential effect of thalidomide and dexamethasone on the transcription factor NF-kappa B
58
121412241214 2001 INTERNATIONAL JOURNAL OF CLINICAL PRACTICE 55(9):627-631
Diggle GE
Thalidomide: 40 years on
710
1215001215 2001 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 42(4):S233-S233
Maguire MG; Fine SL; Maguire AM; D'Amato RJ; Singerman LJ
Results of the age-related macular degeneration and thalidomide study (AMDATS).
05
121612251216 2001 ISRAEL MEDICAL ASSOCIATION JOURNAL 3(9):644-648
Kenet G; Wardi J; Avni Y; Aeed H; Shirin H; Zaidel L; Hershkoviz R; Bruck R
Amelioration of experimental colitis by thalidomide
11
1217001217 2001 JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 286(8):909-909
Mitka M
Thalidomide battles myeloma
10
121837441218 2001 JOINT BONE SPINE 68(6):582-587
Combe B
Thalidomide: new indications?
13
121927531219 2001 JOURNAL OF BIOLOGICAL CHEMISTRY 276(25):22382-22387
Keifer JA; Guttridge DC; Ashburner BP; Baldwin AS
Inhibition of NF-kappa B activity by thalidomide through suppression of I kappa B kinase activity
3357
1220151220 2001 JOURNAL OF CHEMICAL EDUCATION 78(6):759-761
Bennett N; Cornely K
Thalidomide makes a comeback: A case discussion exercise that integrates biochemistry and organic chemistry
03
#LCRNCRNodes / Date / Journal / AuthorsLCSGCS
122110271221 2001 JOURNAL OF CLINICAL IMMUNOLOGY 21(5):357-364
Prehn JL; Landers C; Muller GW; Man HW; Stirling DI; Targan SR
Potent inhibition of cytokine production from intestinal lamina propria T cells by phosphodiesterase-4 inhibitory thalidomide analogues
34
122218261222 2001 JOURNAL OF CLINICAL ONCOLOGY 19(16):3593-3595
Rajkumar SV; Kyle RA
Thalidomide in the treatment of plasma cell malignancies
67
12237221223 2001 JOURNAL OF CLINICAL ONCOLOGY 19(16):3596-3601
Dimopoulos MA; Zomas A; Viniou NA; Grigoraki V; Galani E; Matsouka C; Economou O; Anagnostopoulos N; Panayiotidis P
Treatment of Waldenstrom's macroglobulinemia with thalidomide
1728
122420321224 2001 JOURNAL OF CLINICAL PHARMACOLOGY 41(6):662-667
Teo SK; Scheffler MR; Kook KA; Tracewell WG; Colburn WA; Stirling DI; Thomas SD
Thalidomide dose proportionality assessment following single doses to healthy subjects
34
122511181225 2001 JOURNAL OF CLINICAL PHARMACOLOGY 41(10):1091-1097
Aweeka F; Trapnell C; Chernoff M; Jayewardene A; Spritzler J; Bellibas SE; Lizak P; Jacobson J
Pharmacokinetics and pharmacodynamics of thalidomide in HIV patients treated for oral aphthous ulcers: ACTG protocol 251
67
1226991226 2001 JOURNAL OF DERMATOLOGICAL TREATMENT 12(3):145-147
Thomson KF; Goodfield MJD
Low-dose thalidomide is an effective second-line treatment in cutaneous lupus erythematosus
02
1227001227 2001 JOURNAL OF HEPATOLOGY 34:18-18
Austin AS; Mahida YR; Ryder SD; Freeman JG
Thalidomide but not pentoxifylline lowers portal pressure in human alcoholic cirrhosis
00
12284101228 2001 JOURNAL OF INFECTIOUS DISEASES 183(2):343-346
Jacobson JM; Greenspan JS; Spritzler J; Fox L; Fahey JL; Jackson JB; Chernoff M; Wohl DA; Pulvirenti JJ; Hooton TM; Shikuma C; Natl Inst Allergy Infect Dis AIDS
Thalidomide in low intermittent doses does not prevent recurrence of human immunodeficiency virus-associated aphthous ulcers
13
122910151229 2001 JOURNAL OF INFECTIOUS DISEASES 184(9):1192-1196
Hanekom WA; Hughes J; Haslett PAJ; Apolles P; Ganiso V; Allin R; Goddard E; Hussey GD; Kaplan G
The immunomodulatory effects of thalidomide on human immunodeficiency virus-infected children
33
12309231230 2001 JOURNAL OF NEURO-ONCOLOGY 51(1):41-45
Short SC; Traish D; Dowe A; Hines F; Gore M; Brada M
Thalidomide as an anti-angiogenic agent in relapsed gliomas
1222
#LCRNCRNodes / Date / Journal / AuthorsLCSGCS
12317291231 2001 JOURNAL OF NEURO-ONCOLOGY 54(1):31-38
Marx GM; Pavlakis N; McCowatt S; Boyle FM; Levi JA; Bell DR; Cook R; Biggs M; Little N; Wheeler HR
Phase II study of Thalidomide in the treatment of recurrent glioblastoma multiforme
1522
12324291232 2001 JOURNAL OF NEURO-ONCOLOGY 55(1):11-17
Mawrin C; Aumann V; Kirches E; Schneider-Stock R; Scherlach C; Vogel S; Mittler U; Dietzmann K; Krause G; Weis S
Gliomatosis cerebri: Post-mortem molecular and immunohistochemical analyses in a case treated with thalidomide
04
123310181233 2001 JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION 32(2):178-181
Facchini S; Candusso M; Martelossi S; Liubich M; Panfili E; Ventura A
Efficacy of long-term treatment with thalidomide in children and young adults with Crohn disease: Preliminary results
1017
123424281234 2001 JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION 32(3):322-324
Strauss RS; Das FM
Thalidomide-induced sensory neuropathy
23
12358271235 2001 JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 298(3):1221-1226
Drenth JPH; Vonk AG; Simon A; Powell R; Van der Meer JWM
Limited efficacy of thalidomide in the treatment of febrile attacks of the hyper-IgD and periodic fever syndrome: A randomized, double-blind, placebo-controlled trial
17
1236661236 2001 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 45(6):965-966
George SJ; Hsu S
Lichen planopilaris treated with thalidomide
36
1237051237 2001 LANCET ONCOLOGY 2(10):634-635
Hwu WJ; Raizer J; Panageas KS; Lis E
Treatment of metastatic melanoma in the brain with temozolomide and thalidomide
37
1238001238 2001 LEUKEMIA 15(3):491-491
Barlogie D; Spencer T; Tricot G; Zeldis J; Munshi N; Zangari M; Badros A; Toor A; Shaughnessy J; Morris C; Desikan R
Long term follow up of 169 patients receiving a phase II trial of single agent thalidomide for advanced and refractory multiple myeloma (MM).
00
123910191239 2001 LEUKEMIA 15(8):1274-1276
Rajkumar SV; Dispenzieri A; Fonseca R; Lacy MQ; Geyer S; Lust JA; Kyle RA; Greipp PR; Gertz MA; Witzig TE
Thalidomide for previously untreated indolent or smoldering multiple myeloma
2843
12408171240 2001 LEUKEMIA & LYMPHOMA 42(4):683-+
Avigdor A; Raanani P; Levi I; Hardan I; Ben-Bassat I
Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma
89
#LCRNCRNodes / Date / Journal / AuthorsLCSGCS
1241011241 2001 LIBRARY JOURNAL 126(7):126-126
Kupferberg N
Dark remedy: The impact of thalidomide and its revival as a vital medicine.
00
124229421242 2001 LUPUS 10(3):188-192
Karim MY; Ruiz-Irastorza G; Khamashta MA; Hughes GRV
Update on therapy - thalidomide in the treatment of lupus
613
1243001243 2001 MOLECULAR BIOLOGY OF THE CELL 12:23A-23A
Ezell TN
Apoptotic cell death induced by low doses of the tumor necrosis alpha inhibitor, thalidomide in human T leukemic cells
00
124413291244 2001 MUSCLE & NERVE 24(8):1050-1057
Molloy FM; Floeter MK; Syed NA; Sandbrink F; Culcea E; Steinberg SM; Dahut W; Pluda J; Kruger EA; Reed E; Figg WD
Thalidomide neuropathy in patients treated for metastatic prostate cancer
1217
1245011245 2001 NATURE 410(6827):411-412
Dormandy T
Dark remedy: The impact of thalidomide and its revival as a vital medicine
00
124611211246 2001 NETHERLANDS JOURNAL OF MEDICINE 59(2):45-49
van de Poel MHW; Pasman PC; Schouten HC
The use of thalidomide in chronic refractory graft versus host disease
13
1247001247 2001 NEUROLOGY 56(8):A208-A209
Khella SL; Souayah N; AMDATS Study Grp
Thalidomide polyneuropathy: A prospective double-masked placebo-controlled study in an elderly population with age-related macular degeneration
00
12481261248 2001 NEUROTOXICOLOGY AND TERATOLOGY 23(3):255-264
Vorhees CV; Weisenburger WP; Minck DR
Neurobehavioral teratogenic effects of thalidomide in rats
13
1249341249 2001 NEW ENGLAND JOURNAL OF MEDICINE 344(25):1951-1952
Osman K; Comenzo R; Rajkumar SV
Deep venous thrombosis and thalidomide therapy for multiple myeloma.
4659
1250331250 2001 NEW ENGLAND JOURNAL OF MEDICINE 345(16):1214-1215
Kudva GC; Collins BT; Dunphy FR
Thalidomide for malignant melanoma.
12
#LCRNCRNodes / Date / Journal / AuthorsLCSGCS
1251011251 2001 NEW YORK REVIEW OF BOOKS 48(8):12-15
Horton R
Dark remedy: The impact of thalidomide and its revival as a vital medicine
00
1252001252 2001 ONCOLOGY-NEW YORK 15(3):301-301
[Anon]
Thalidomide analogs active against multiple myeloma
00
1253001253 2001 ONCOLOGY-NEW YORK 15(4):493-+
[Anon]
Thalidomide studied in a variety of cancers and metabolic disorders
00
125428701254 2001 ONCOLOGY-NEW YORK 15(7):867-874
Rajkumar SV
Current status of thalidomide in the treatment of cancer
914
1255481255 2001 ONCOLOGY-NEW YORK 15(7):877-878
Govindarajan R
Current status of thalidomide in the treatment of cancer - The Rajkumar article reviewed
00
1256281256 2001 ONCOLOGY-NEW YORK 15(7):878-879
Hwu WJ
Current status of thalidomide in the treatment of cancer - The Rajkumar article reviewed
00
125723551257 2001 OPHTHALMIC RESEARCH 33(5):256-263
Baatz H; Tonessen B; Prada J; Pleyer U
Thalidomide inhibits leukocyte-endothelium interaction in endotoxin-induced uveitis
14
12586151258 2001 OPHTHALMOLOGICA 215(1):70-73
Parentin F; Da Pozzo S; Lepore L; Perissutti P
Thalidomide effectiveness for bilateral chronic idiopathic anterior uveitis in a three-year-old child
22
12597401259 2001 OPHTHALMOLOGICA 215(4):284-289
Kaven C; Spraul CW; Zavazava N; Lang GK; Lang GE
Thalidomide and prednisolone inhibit growth factor-induced human retinal pigment epithelium cell proliferation in vitro
27
12608161260 2001 PEDIATRIC DERMATOLOGY 18(2):143-145
Brik R; Shamali H; Bergman R
Successful thalidomide treatment of severe infantile Behcet disease
11
#LCRNCRNodes / Date / Journal / AuthorsLCSGCS
12612101261 2001 POLISH JOURNAL OF PHARMACOLOGY 53(6):709-713
Dmoszynska A; Rolinski J; Bojarska-Junak A; Manko J; Jawniak D; Walter-Croneck A; Soroka-Wojtaszko M; Hus M
Influence of thalidomide on Bcl(2) expression and proangiogenic cytokine levels in short-term culture of peripheral blood and bone marrow mononuclear cells of multiple myeloma patients
00
1262231262 2001 PRESSE MEDICALE 30(20):1008-1009
Pouaha J; Martin S; Trechot P; Truchetet F; Barbaud A; Schmutz JL
Thalidomide and thrombosis: three cases
55
126320481263 2001 QUIMICA NOVA 24(5):683-688
Lima LM; Fraga CAM; Barreiro EJ
The rebirth of a drug: Thalidomide
01
1264001264 2001 RADIOLOGY 221:387-387
Faria SC; Charnsangavej C; Sawaf Y; Hess KR; Tamm EP; Lee T
CT quantification of antiangiogenic effects of thalidomide
00
126513181265 2001 REVUE DE MEDECINE INTERNE 22(1):5-7
Grosbois B; Duguet C
Thalidomide: the revival
24
126611411266 2001 RHEUMATOLOGY 40(8):933-938
Kari JA; Shah V; Dillon MJ
Behcet's disease in UK children: clinical features and treatment including thalidomide
516
1267571267 2001 SCIENTIST 15(2):1-+
Lewis R
The return of thalidomide
01
12686481268 2001 SEMINARS IN HEMATOLOGY 38(3):250-259
Barlogie B; Zangari M; Spencer T; Fassas A; Anaissie E; Badros A; Cromer J; Tricot G
Thalidomide in the management of multiple myeloma
1831
12698401269 2001 SEMINARS IN ONCOLOGY 28(4):62-66
Figg WD; Arlen P; Gulley J; Fernandez P; Noone M; Fedenko K; Hamilton M; Parker C; Kruger EA; Pluda J; Dahut WL
A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer
1638
12707181270 2001 SEMINARS IN ONCOLOGY 28(6):577-582
Barlogie B; Tricot G; Anaissie E
Thalidomide in the management of multiple myeloma
1017
#LCRNCRNodes / Date / Journal / AuthorsLCSGCS
12717211271 2001 SEMINARS IN ONCOLOGY 28(6):583-587
Kyle RA; Rajkumar SV
Therapeutic application of thalidomide in multiple myeloma
59
12726181272 2001 SEMINARS IN ONCOLOGY 28(6):588-592
Blade J; Esteve J; Rosinol L; Perales M; Montoto S; Tuset M; Montserrat E
Thalidomide in refractory and relapsing multiple myeloma
1113
127312251273 2001 SEMINARS IN ONCOLOGY 28(6):593-596
Desikan RK; Jagannath S
Therapeutic dilemmas with thalidomide in multiple myeloma: Case discussions
22
127419471274 2001 SEMINARS IN ONCOLOGY 28(6):597-601
D'Amato RJ; Lentzsch S; Anderson KC; Rogers MS
Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma
010
127515171275 2001 SEMINARS IN ONCOLOGY 28(6):602-606
Stirling D
Thalidomide: A novel template for anticancer drugs
813
1276341276 2001 SWISS MEDICAL WEEKLY 131(9-10):133-133
Trojan A; Anagnostara A; Fost L
Thalidomide: near complete regression of extramedullary bulk in refractory multiple myeloma
22
12776271277 2001 SYNTHESIS-STUTTGART (7):999-1000
Seijas JA; Vazquez-Tato MP; Gonzalez-Bande C; Martinez MM; Pacios-Lopez B
Microwave promoted synthesis of a rehabilitated drug: Thalidomide
02
127823521278 2001 TOXICOLOGICAL SCIENCES 59(1):160-168
Teo SK; Evans MG; Brockman MJ; Ehrhart J; Morgan JM; Stirling DI; Thomas SD
Safety profile of thalidomide after 53 weeks of oral administration in beagle dogs
55
1279001279 2002 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 224:U21-U21
Hu ZG; Zink J; Zili X; Shi JD; Li PK
Anti-angiogenic and anti-proliferative thalidomide analogs.
00
12806151280 2002 ACTA DERMATO-VENEREOLOGICA 82(5):384-386
Kolde G; Schulze P; Sterry W
Mixed response to thalidomide therapy in adults: Two cases of multisystem Langerhans' cell histiocytosis
12
#LCRNCRNodes / Date / Journal / AuthorsLCSGCS
12817111281 2002 AIDS 16(17):2355-2356
Teo S; Noormohamed F; Youle M; Johnson M; Peters B; Stirling D; Thomas S
Transient increase in plasma HIV-1 viral load and associated weight gain after thalidomide dosing
11
12829241282 2002 AKTUELLE NEUROLOGIE 29(3):149-152
Vogt T; Nill M; Hundsberger T
Thalidomide neuropathy
00
128321361283 2002 ALIMENTARY PHARMACOLOGY & THERAPEUTICS 16(6):1117-1124
Sabate JM; Villarejo J; Lemann M; Bonnet J; Allez M; Modigliani R
An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease
415
12848261284 2002 ALIMENTARY PHARMACOLOGY & THERAPEUTICS 16(12):2115-2122
Ginsburg PM; Ehrenpreis ED
A pilot study of thalidomide for patients with symptomatic mesenteric panniculitis
01
12850161285 2002 AMERICAN BIOLOGY TEACHER 64(7):495-500
Seidman LA; Warren NN
Frances Kelsey & thalidomide in the US: A case study relating to pharmaceutical regulations
00
128613271286 2002 AMERICAN HEART JOURNAL 144(5):847-850
Gullestad L; Semb AG; Holt E; Skardal R; Ueland T; Yndestad A; Froland SS; Aukrust P
Effect of thalidomide in patients with chronic heart failure
14
1287001287 2002 AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY 59(18):1700-+
Young D
Thalidomide prescribers cannot assign survey responsibility to pharmacists
00
1288331288 2002 AMERICAN JOURNAL OF HEMATOLOGY 70(3):265-265
Pulik M; Genet P; Lionnet F; Touahri T
Thalidomide-associated gynecomasty in a patient with multiple myeloma
11
12895161289 2002 AMERICAN JOURNAL OF MEDICINE 112(5):412-413
Badros AZ; Siegel E; Bodenner D; Zangari M; Zeldis J; Barlogie B; Tricot G
Hypothyroidism in patients with multiple myeloma following treatment with thalidomide
910
129011271290 2002 AMERICAN JOURNAL OF MEDICINE 113(7):603-606
Bennett CL; Schumock GT; Desai AA; Kwaan HC; Raisch DW; Newlin R; Stadler W
Thalidomide-associated deep vein thrombosis and pulmonary embolism
36
#LCRNCRNodes / Date / Journal / AuthorsLCSGCS
129113401291 2002 ANALYTICAL CHEMISTRY 74(15):3726-3735
Meyring M; Muhlbacher J; Messer K; Kastner-Pustet N; Bringmann G; Mannschreck A; Blaschke G
In vitro biotransformation of (R)- and (S)-thalidomide: Application of circular dichroism spectroscopy to the stereochemical characterization of the hydroxylated metabolites
03
12920211292 2002 ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY 88(4):421-424
Medeiros M; Araujo MI; Guimaraes NS; Freitas LAR; Silva TMC; Carvalho EM
Therapeutic response to thalidomide in Melkersson-Rosenthal syndrome: a case report
12
1293131293 2002 ANNALS OF INTERNAL MEDICINE 136(9):711-711
Escudier B; Lassau N; Leborgne S; Angevin E; Laplanche A
Thalidomide and venous thrombosis
69
12946281294 2002 ANNALS OF ONCOLOGY 13(7):1029-1035
Escudier B; Lassau N; Couanet D; Angevin E; Mesrati F; Leborgne S; Garofano A; Leboulaire C; Dupouy N; Laplanche A
Phase II trial of thalidomide in renal-cell carcinoma
1223
12953141295 2002 ANNALS OF ONCOLOGY 13(7):1116-1119
Alexanian R; Weber D; Giralt S; Delasalle K
Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy
710
1296461296 2002 ANNALS OF ONCOLOGY 13(10):1636-1640
Grover JK; Uppal G; Raina V
The adverse effects of thalidomide in relapsed and refractory patients of multiple myeloma
34
129727341297 2002 ANNALS OF PHARMACOTHERAPY 36(3):521-525
Bessmertny O; Pham T
Thalidomide use in pediatric patients
12
1298631121298 2002 ANNUAL REVIEW OF MEDICINE 53:629-657
Richardson P; Hideshima T; Anderson K
Thalidomide: Emerging role in cancer medicine
2336
12999361299 2002 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 46(6):1887-1895
Tsenova L; Mangaliso B; Muller G; Chen Y; Freedman VH; Stirling D; Kaplan G
Use of IMiD3, a thalidomide analog, as an adjunct to therapy for experimental tuberculous meningitis
35
1300011300 2002 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 46(7):2313-2313
Tsenova L; Mangaliso B; Muller G; Chen Y; Freedman VH; Stirling D; Kaplan G
Use of IMiD3, a thalidomide analog, as an adjunct to therapy for experimental tuberculous meningitis (vol 46, pg 1889, 2002)
00
#LCRNCRNodes / Date / Journal / AuthorsLCSGCS
130118271301 2002 ARCHIVOS DE BRONCONEUMOLOGIA 38(10):492-494
Valero FC; Gonzalez VB
Lung toxicity due to thalidomide
11
13028141302 2002 ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH 47(3):249-254
Huang F; Gu JR; Zhao W; Zhu J; Zhang JL; Yu DTY
One-year open-label trial of thalidomide in ankylosing spondylitis
311
1303001303 2002 ARTHRITIS AND RHEUMATISM 46(9):S290-S290
Cuadrado MJ; Karim Y; Sanna G; Smith E; Khamashta MA; Hughes GRV
Thalidomide in lupus: Efficacy and toxicity are not dose-dependent.
00
1304001304 2002 ARTHRITIS AND RHEUMATISM 46(9):S480-S481
Schwartz KH; Agle LMA; Lehman TJA
Thalidomide therapy of systemic onset JIA: Continued success.
02
130530711305 2002 BIOLOGICAL & PHARMACEUTICAL BULLETIN 25(5):597-604
Marks MG; Shi JD; Fry MO; Xiao ZL; Trzyna M; Pokala V; Ihnat MA; Li PK
Effects of putative hydroxylated thalidomide metabolites on blood vessel density in the chorioallantoic membrane (CAM) assay and on tumor and endothelial cell proliferation
69
130612261306 2002 BIOMEDICINE & PHARMACOTHERAPY 56(1):1-3
Mathe G
Thalidomide, a drug which may protect the organism against some aggressive effects of the immunologic system
00
130753611307 2002 BIOMEDICINE & PHARMACOTHERAPY 56(1):4-12
Singhal S; Mehta J
Thalidomide in cancer
1721
130817421308 2002 BIOMEDICINE & PHARMACOTHERAPY 56(1):13-19
Sampaio EP; Hernandez MO; Carvalho DS; Sarno EN
Management of erythema nodosum leprosum by thalidomide: thalidomide analogues inhibit M-leprae-induced TNF alpha production in vitro
56
130915821309 2002 BIOMEDICINE & PHARMACOTHERAPY 56(1):20-30
Zorat F; Pozzato G
Thalidomide in myelodysplastic syndromes
33
131017481310 2002 BIOMEDICINE & PHARMACOTHERAPY 56(1):31-35
Shek LPC; Lim DLC
Thalidomide in Behcet's disease
711
#LCRNCRNodes / Date / Journal / AuthorsLCSGCS
131150931311 2002 BIOMEDICINE & PHARMACOTHERAPY 56(3):115-128
Richardson P; Hideshima T; Anderson K
Thalidomide in multiple myeloma
56
131230451312 2002 BIOMEDICINE & PHARMACOTHERAPY 56(4):194-199
Ng SSW; Brown M; Figg WD
Thalidomide, an antiangiogenic agent with clinical activity in cancer
56
131326911313 2002 BIOORGANIC & MEDICINAL CHEMISTRY 10(3):461-479
Hashimoto Y
Structural development of biological response modifiers based on thalidomide
815
13143331314 2002 BIOORGANIC & MEDICINAL CHEMISTRY 10(9):3067-3073
Lima LM; Castro P; Machado AL; Fraga CAM; Lugnier C; de Moraes VLG; Barreiro EJ
Synthesis and anti-inflammatory activity of phthalimide derivatives, designed as new thalidomide analogues
26
13158301315 2002 BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 12(7):1043-1046
Noguchi T; Shimazawa R; Nagasawa K; Hashimoto Y
Thalidomide and its analogues as cyclooxygenase inhibitors
1215
131611191316 2002 BJU INTERNATIONAL 89(6):591-595
Douglas ML; Reid JL; Hii SI; Jonsson JR; Nicol DL
Renal cell carcinoma may adapt to and overcome anti-angiogenic intervention with thalidomide
14
131718361317 2002 BLOOD 99(3):834-839
Steins MB; Padro T; Bieker R; Ruiz S; Kropff M; Kienast J; Kessler T; Buechner T; Berdel WE; Mesters RM
Efficacy and safety of thalidomide in patients with acute myeloid leukemia
1125
1318551318 2002 BLOOD 99(11):4247-4248
Urbauer E; Kaufmann H; Nosslinger T; Raderer M; Drach J
Thromboembolic events during treatment with thalidomide
1318
1319441319 2002 BLOOD 99(11):4248-4248
Lee FC
Second response to lower-dose thalidomide in a patient with multiple myeloma
22
1320361320 2002 BLOOD 99(11):4249-4249
Zangari M
Thalidomide and thromboembolism - Response
00
#LCRNCRNodes / Date / Journal / AuthorsLCSGCS
132112351321 2002 BLOOD 99(12):4525-4530
Mitsiades N; Mitsiades CS; Poulaki V; Chauhan D; Richardson PG; Hideshima T; Munshi NC; Treon SP; Anderson KC
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications
1454
13224231322 2002 BLOOD 100(4):1168-1171
Zangari M; Siegel E; Barlogie B; Anaissie E; Saghafifar F; Fassas A; Morris C; Fink L; Tricot G
Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy
1933
1323131323 2002 BLOOD 100(4):1519-1520
Leleu X; Magro L; Fawaz A; Bauters F; Facon T; Yakoub-Agha I
Efficacy of a low dose of thalidomide in advanced multiple myeloma
77
13243201324 2002 BLOOD 100(6):2263-2265
Neben K; Mytilineos J; Moehler TM; Preiss A; Kraemer A; Ho AD; Opelz G; Goldschmidt H
Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma
1021
1325881325 2002 BLOOD 100(6):2272-2273
Cavo M; Zamagni E; Cellini C; Tosi P; Cangini D; Cini M; Valdre L; Palareti G; Masini L; Tura S; Baccarani M
Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy
1115
1326001326 2002 BLOOD 100(11):15B-15B
Carneiro JDA; Garanito M; Halsman M; Matsumoto L; Odone V; del Giglio A
Thalidomide as salvage therapy for acquired severe aplastice anemia (SAA) in children - Case report
00
1327001327 2002 BLOOD 100(11):71A-71A
Mesa RA; Li CY; Steensma DP; Pardanani A; Elliott MA; Kaufmann SH; Gray L; Schroeder GS; Tefferi A
A combination of low dose thalidomide with prednisone in myelofibrosis with myeloid metaplasia.
00
1328001328 2002 BLOOD 100(11):75B-75B
Kaushal V; Kaushal GP; Anaissie EJ; Kurylo P; Kohli M; Fink LM; Mehta P
Thalidomide-induced coagulopathy: Evidence for an indirect effect on endothelium.
00
1329001329 2002 BLOOD 100(11):96A-96A
List AF; Kurtin SE; Glinsmann-Gibson BJ; Bellamy WT; Buresh AJ; Waddleton D; Knight R
High erythropoietic remitting activity of the immunomodulatory thalidomide analog, CC5013, in patients with myelodysplastic syndrome (MDS).
03
1330001330 2002 BLOOD 100(11):96A-96A
Moreno-Aspitia A; Geyer S; Li CY; Tefferi A; Witzig T; Niedrinhaus RD; Vukov AM; Morton R; Fitch T; Addo FE; Dakhil SR; Tschetter L; Colon-Otero G
N998B: Multicenter phase II trial of thalidomide (Thal) in adult patients with myelodysplastic syndromes (MDS).
01
#LCRNCRNodes / Date / Journal / AuthorsLCSGCS
1331001331 2002 BLOOD 100(11):105A-105A
Zangari M; Barlogie B; Prather J; Eddlemon P; Anaissie E; Lee CK; Tricot G; Thertulien R; van Rhee F
Marked activity also in del 13 multiple myeloma (MM) of PS 341 (PS) and subsequent thalidomide (THAL) in a setting of resistance to post-autotransplant salvage therapies.
05
1332001332 2002 BLOOD 100(11):139A-139A
List AF; Tate W; Glinsmann-Gibson BJ; Baker A
The immunomodulatory thalidomide analog, CC5013, inhibits trophic response to VEGF in AML cells by abolishing cytokine-induced PI3-kinase/Akt activation.
01
1333001333 2002 BLOOD 100(11):162A-162A
Drach J; Kaufmann H; Puespoek A; Bankier A; Urbauer E; Chott A; Raderer M
Marked anti-tumor activity of rituximab plus thalidomide in patients with relapsed/resistant mantle cell lymphoma.
01
1334001334 2002 BLOOD 100(11):170A-170A
Neben K; Mytilineos J; Kraemer A; Moehler TM; Preiss A; Ho AD; Opelz G; Goldschmidt H
Thalidomide is able to improve the outcome in patients carrying the high producer haplotype of the interleukin-10 gene promoter in multiple myeloma.
00
1335001335 2002 BLOOD 100(11):178A-178A
Brinker B; Waller EK; Langston AA; Redei I; Smith KJ; Bucur SZ; Winton E; Lyles R; Heffner LT; Lonial S
Therapy with thalidomide enhances overall survival after autologous PBSC transplant for multiple myeloma.
00
1336001336 2002 BLOOD 100(11):209A-209A
Weber D; Ginsberg C; Walker P; Obolendt M; Rankin K; Gavino M; Delasalle K; Alexanian R
Correlation of thrombotic/embolic events (T/E) with features of hypercoagulability in previously untreated patients before and after treatment with thalidomide (T) or thalidomide-dexamethasone (TD).
03
1337001337 2002 BLOOD 100(11):210A-210A
Barlogie B; Tricot G; Anaissie E; Fassas A; Lee CK; Thertulien R; van Rhee F; Zangari M
Long-term follow-up (median of 4 yr) of 169 patients receiving thalidomide (THAL) for advanced and refractory multiple myeloma (MM): Superior survival in the absence of cytogenetic abnormalities (CA) and low beta-2 microglobulin (B2M).
00
1338001338 2002 BLOOD 100(11):211A-211A
Palumbo A; Bertola A; Cavallo F; Falco P; Bringhen S; Giaccone L; Musto P; Pregno P; Boccadoro M
Low-dose thalidomide and dexamethasone improves survival in advanced multiple myeloma.
03
1339001339 2002 BLOOD 100(11):211A-211A
Myers B; Jones SG; McMillan AK; Dolan G
Zoledronic acid, hypocalcaemia and renal dysfunction in thalidomide-treated myeloma patients.
00
1340001340 2002 BLOOD 100(11):265B-265B
Manson SD; Gregory SA; Rogers K; Raza A; Loew J; Hsu WT; Sivaraman S; Venugopal P
Thalidomide as a single agent leads to meaningful responses in older patients with poor prognosis acute myeloid leukemia (PP-AML)
00
#LCRNCRNodes / Date / Journal / AuthorsLCSGCS
1341001341 2002 BLOOD 100(11):314B-314B
Hayashi T; Anderson KC; Steven SP
Rituximab induced antibody dependent cell mediated cytotoxicity (ADCC) is enhanced by thalidomide and its analogue revimid.
01
1342001342 2002 BLOOD 100(11):336B-336B
Musto P; Falcone A; Sanpaolo G; Bodenizza C; Bisceglia M; Matera R; Minervini MM; Carella AM
Does thalidomide act with different mechanisms of action in myelodysplastic syndromes?
00
1343001343 2002 BLOOD 100(11):337B-337B
Shetty V; Alvi S; Zorat F; Patkar S; Zahid S; Khan T; Mundle S; Galili N; Reddy P; Alvi M; Lisak L; Gezer S
Effect of the anti-angiogenic agent thalidomide on the biological characteristics of patients with myelodysplastic syndromes.
00
1344001344 2002 BLOOD 100(11):340B-340B
Raza A; Lisak LA; Tahir S; Billmeier JM; Willmann HS; Alvi MI; Bellak DJ; Gezer S; Venugopal P
Combination of thalidomide and etanercept (Tumor necrosis factor receptor OR TNFR) effective in improving the cytopenias of some patients with myelodysplastic syndromes (MDS).
02
1345001345 2002 BLOOD 100(11):341B-341B
Islam A; Bielat K; Smith G
Does thalidomide have an effect other than anti-angiogenesis.
00
1346001346 2002 BLOOD 100(11):346B-346B
Grossi A; Gavazzi S; Biscardi M; Balestri F; Bonsi L; Bagnara G; Pierdomenico L; Mazzucconi F
Thalidomide therapy effects on angiogenic growth factors (VEGF, TGF-beta) and KDR expression in myeloid metaplasia with myelofibrosis.
01
1347001347 2002 BLOOD 100(11):367B-367B
Luo SK; Li J; Hong WD; Zhou ZH
Immunoreactivity of thalidomide in patients with multiple myeloma.
00
1348001348 2002 BLOOD 100(11):371B-371B
Payvandi F; Wu L; Zhang LH; Muller G; Chen R; Stengel J; Harriri R; Stirling D
Thalidomide and IMiDs inhibit microvessel formation from human arterial rings in the absence of human liver microsomes.
00
1349001349 2002 BLOOD 100(11):375A-375A
Alvi S; Borok RZ; Shaher A; Anthwal S; Shaikh M; Alvi I; Tahir S; John P; Shetty V; Galili N; Raza A
Thalidomide significantly modifies bone marrow microenvironment in myelodysplastic syndrome (MDS) patients.
00
1350001350 2002 BLOOD 100(11):377B-377B
Lincz LF; Enno A
Thalidomide induced alterations in multiple myeloma cell surface receptor expression do not affect adhesion to bone marrow stroma or correlate with VEGF secretion in vitro.
00
#LCRNCRNodes / Date / Journal / AuthorsLCSGCS
1351001351 2002 BLOOD 100(11):380B-380B
Waage A; Romstad L; Brenne AT; Gimsing P; Juliusson G; Turesson I; Borset M; Sundan A
Low serum levels of soluble tumor necrosis factor receptors predict for response to thalidomide in advanced myeloma.
01
1352001352 2002 BLOOD 100(11):384B-384B
Devabhaktuni YD; Laber DA
Secondary plasma cell leukemia associated with thalidomide in a patient with multiple myeloma.
00
1353001353 2002 BLOOD 100(11):384B-384B
Dimopoulos MA; Tsatalas C; Zomas A; Hamilos G; Panayiotidis P; Anagnostopoulos N; Gika D; Margaritis D; Economopoulos T
Clarithromycin, thalidomide and dexamethasone for the treatment of Waldenstrom's macroglobulinemia.
00
1354001354 2002 BLOOD 100(11):384B-384B
Fawaz A; Magro L; Leleu X; Depil S; Guillerm G; Corm S; Bauters F; Facon T; Yakoub-Agha I
Impact of thalidomide on survival of patients with multiple myeloma.
02
1355001355 2002 BLOOD 100(11):385B-385B
Caravita T; Arciprete F; Siniscalchi A; Santinelli S; Iani C; Amadori S
Thalidomide induced neuropathy in patients treated for multiple myeloma.
00
1356001356 2002 BLOOD 100(11):387B-387B
Helgason HH; Smit WM; de Groot MR; Schenkeveld CEI; Neef C; Schaafsma MR
Long term survival and complete remission of chemotherapy refractory multiple myeloma with thalidomide.
00
1357001357 2002 BLOOD 100(11):387B-387B
Dmoszynska A; Manko J; Jawniak D; Ciepluch H; Hellmann A; Wolska-Smolen T; Skotnicki A; Soroka-Wojtaszko M; Urbanska-Rys H; Konopka L; Hus M
Toxicity of thalidomide in multiple myeloma patients (long-term observations).
00
1358001358 2002 BLOOD 100(11):387B-387B
Meng HT; Jin J; Mai WY
Thalidomide plus M2 chemotherapy in the treatment of refractory multiple myeloma.
00
1359001359 2002 BLOOD 100(11):388B-388B
Musto P; Falcone A; Sanpaolo G; La Sala A; Mantuano S; Cascavilla N; Melillo L; Dell'Olio M; Nobile M; Bodenizza C; Carella AM
A combined therapy with thalidomide, dexamethasone and zoledronate is highly effective and well tolerated in pre-treated patients with multiple myeloma.
01
1360001360 2002 BLOOD 100(11):389B-389B
Keyzner A; Kumar A; Besa EC
The role of thalidomide and pamidronate in maintenance of plateau phase after second and third induction therapy in relapsed multiple myeloma patients.
00
#LCRNCRNodes / Date / Journal / AuthorsLCSGCS
1361001361 2002 BLOOD 100(11):389B-389B
Huang JW; Wang YH; Du HP; Zhang J
Thalidomide combined with conventional melphalan and predisone regimen for treatment of mulitiple myeloma
00
1362001362 2002 BLOOD 100(11):390B-390B
Breitkreutz I; Cremer FW; Benner A; Raab MS; Moehler T; Egerer G; Christensen O; Herrmann D; Ho AD; Goldschmidt H
Peripheral blood stem cell collection (PBSC) after CAD plus G-CSF in multiple myeloma: No influence of previous thalidomide (Thai) administration.
00
1363001363 2002 BLOOD 100(11):390B-390B
Sato N; Kakimoto T; Hattori Y; Okamoto S; Morita K; Tanigawara Y; Ikeda Y
Thalidomide induced severe neutropenia during the treatment of multiple myeloma via direct suppression of bone marrow hematopoiesis.
00
1364001364 2002 BLOOD 100(11):390B-390B
Sidra GM; Russell N; Byrne J; Myers B; Mitchell D
Combination therapy with thalidomide, cyclophosphamide and dexamethasone (C-ThaD) for VAD-refractory and relapsed myeloma.
00
1365001365 2002 BLOOD 100(11):390B-390B
Alegre A; Gil-Fernandez JJ; Font P; Alonso A; Sureda A; Martinez-Chamorro C; Escudero A; Sanchez-Godoy P; Burgaleta C; Casado LF; Granda A; Aguado B; Osorio S; Nistal S; Mascunano R; Prieto E; Fernandez-Ranada JM
Thalidomide as rescue of relapses after haematopoietic transplantation in multiple myeloma and as maintenance treatment: Results of a Spanish multicentre study including 63 patients.
00
1366001366 2002 BLOOD 100(11):392B-392B
Kazmi MA; Cuadrado MJ; Karim MY; Jones RJ; Khamashta MA; Schey SA
Comparison of thalidomide toxicity profiles in treatment of Lupus and myeloma: Efficacy and toxicity are not dose dependent.
00
1367001367 2002 BLOOD 100(11):393B-393B
Moehler TM; Schlenzka J; Kasper B; Neben K; Egerer G; Ho AD; Goldschmidt H
Low incidence of deep venous thrombosis in poor prognosis multiple myeloma patients treated with thalidomide and CED chemotherapy.
00
1368001368 2002 BLOOD 100(11):393A-393A
Bahlis NJ; Sawney R; Gerson S
PKC delta inhibition induces cell death in thalidomide and dexamethasone resistant multiple myeloma cell lines.
00
1369001369 2002 BLOOD 100(11):394A-395A
Minnema MM; Fijnheer R; De Groot PG; Lokhorst HM
Factor VIII procoagulant activity as risk factor for deep venous thrombosis in patients with Multiple Myeloma during treatment with thalidomide.
00
1370001370 2002 BLOOD 100(11):397A-397A
Palladini G; Perfetti V; Obici L; Merlini G
Thalidomide toxicity in patients with AL (primary) amyloidosis.
04
#LCRNCRNodes / Date / Journal / AuthorsLCSGCS
1371001371 2002 BLOOD 100(11):398A-398A
Zangari M; Barlogie B; Anaissie FJ; Saghafifar F; Fassas A; Lee CK; Thertulien R; van Rhee F; Zeldis J; Fink L; Tricot G
Abrogation of thrombogenic effect of the doxorubicin (DOX)- thalidomide (THAL) combination as part of total therapy II (TTII) for newley diagnosed multiple myeloma (MM) by effective anti-coagulation with low molecular weight heparin (LMWH).
02
1372001372 2002 BLOOD 100(11):398A-398A
Dispenzieri A; Lacy MQ; Rajkumar SV; Geyer SM; Fonseca R; Witzig TE; Lust JA; Greipp PR; Kyle RA; Gertz MA
High doses of thalidomide are not well tolerated in patients with primary systemic amyloidosis.
02
1373001373 2002 BLOOD 100(11):401A-402A
Prince M; Mileshkin L; Biagi JJ; Smith JG; Mitchell P; Underhill C; Grigg A; Bell R; McKendrick J; Briggs P; Seymour JF; Simmons PJ; Zeldis JB
A multicentre phase-II trial of thalidomide in relapsed/refractory multiple myeloma (MM) reveals a dominant adverse prognostic impact of advanced age.
00
1374001374 2002 BLOOD 100(11):402A-402A
Oakervee HE; McBride NC; Hemmaway CJ; Brownell A; Cervi P; Crawley C; Gale R; Grant I; Hamblin M; Lewis D; Rahemtulla A; Barnett MJ; Cavenagh JD
Thalidomide combined with vincristine, adriamycin and dexamethasone (T-VAD) is effective treatment for multiple myeloma and does not prejudice successful stem cell harvesting.
02
1375001375 2002 BLOOD 100(11):402A-403A
Kropff MH; Lang N; Bisping G; Domine N; Schneider P; Suedhoff T; Innig G; Straka C; Ostermann H; Berdel WE; Kienast J
Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in advanced multiple myeloma: Final results of a phase II trial.
01
1376001376 2002 BLOOD 100(11):403A-403A
Hussein MA; Elson P; Tsoe EA; Karam M; Srkaloci G
Doxil (D), vincristine (V), decadron (D) and thalidomide (T) (DVd-T) for relapsed/refractory multiple myeloma (RMM).
05
1377001377 2002 BLOOD 100(11):403A-404A
Rajkumar SV; Gertz MA; Lacy MQ; Dispenzieri A; Fonseca R; Geyer S; Iturria N; Kumar S; Lust JA; Kyle RA; Greipp PR; Witzig TE
Single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma.
00
1378001378 2002 BLOOD 100(11):426B-426B
Santos E; Goodman M; Byrnes JJ; Fernandez HF
Thalidomide as maintenance therapy in the post-transplantation setting in patients with multiple myeloma.
00
1379001379 2002 BLOOD 100(11):434A-434A
Ghobrial IM; Kumar S; Porrata LF; Gertz MA; Gastineau DA; Ansell SM; Lacy MQ; Rajkumar VS; Micallef IN; Tefferi A; Dispenzieri A; Inwards D; Litzow MR; Markovic SN
Thalidomide does not affect immune reconstitution post-autologous bone marrow transplantation in Multiple Myeloma.
00
1380001380 2002 BLOOD 100(11):477B-477B
Cottler-Fox M; Barlogie B; Anaissie E; Zangari M; Fassas A; Lee CK; van Rhee F; Thertulien R; Tricot G
Determinants of high and low CD 34 yield after CAD as part of Total Therapy II (TT II) for newly diagnosed Multiple Myeloma (MM): Effect of Thalidomide (THAL).
00
#LCRNCRNodes / Date / Journal / AuthorsLCSGCS
1381001381 2002 BLOOD 100(11):671A-671A
LeBlanc R; Hideshima T; Hayashi T; Catley LP; Burger R; Shringarpure R; Cheema P; Richardson P; Anderson KC; Munshi NC
Thalidomide analogue IMiD3 provides T cell co-stimulation through B7-CD28 pathway.
00
1382001382 2002 BLOOD 100(11):795A-795A
Raza A; Lisak LA; Tahir S; Billmeier JM; Willmann HS; Alvi MI; Patkar S; Khan T; Rizvi A; Venugopal P; Gezer S; Mundle SD; Reddy PL
Trilineage responses to arsenic trioxide (Trisenox (R)) and thalidomide in patients with myelodysplastic syndromes (MDS), particularly those with inv(3)(q21q26.2).
00
1383001383 2002 BLOOD 100(11):800A-800A
Barosi G; Elliott M; Canepa L; Ballerini F; Piccaluga PP; Visani G; Marchetti M; Pozzato G; Zorat F; Tefferi A
Thalidomide in Myelofibrosis with Myeloid Metaplasia: A pooled-analysis of individual patient data from five studies.
00
1384001384 2002 BLOOD 100(11):808A-809A
Weber D; Albitar M; Delasalle K; Dey A; Rankin K; Gavino M; Walker P; Alexanian R
Correlation of peripheral blood plasma levels of angiogenesis factors with treatment of thalidomide (T) or thalidomide-dexamethasone (TD) in prevoiusly untreated patients with multiple myeloma (MM).
01
1385001385 2002 BLOOD 100(11):811A-811A
Thompson MA; Witzig TE; Timm MM; Haug J; Kumar S; Fonseca R; Greipp PR; Rajkumar SV
Angiogenesis and angiogenic cytokines in patients receiving thalidomide for multiple myeloma (MM).
01
1386001386 2002 BLOOD 100(11):813A-813A
Richardson P; Jagannath S; Schlossman R; Alsina M; Desikan RK; Blood E; Weller E; Mitsiades C; Hideshima T; Davies F; Doss D; Freeman A; Bosch J; Patin J; Dalton W; Anderson KC
Thalidomide for relapsed multiple myeloma after high dose therapy and stem cell transplantation: Results of an open-label, multicenter phase two study of efficacy, toxicity and correlation with biological activity.
00
1387001387 2002 BLOOD 100(11):815A-815A
Hayashi T; Hideshima T; Akiyama M; Munshi N; Chauhan D; Anderson KC
Mechanisms whereby immunomedulatory analogs of thalidomide augment autologous NK cell anti-myeloma immunity.
01
1388001388 2002 BLOOD 100(11):816A-816A
Treston AM; Swartz GM; Conner B; Shah J; Pribluda VS
Pre-clinical evaluation of a thalidomide analog with activity against multiple myeloma and solid tumors - ENMD-0995 (S-(-)3- (3-amino-phthalimido)-glutarimide).
01
138924391389 2002 BLOOD 100(12):4162-4168
Yaccoby S; Johnson CL; Mahaffey SC; Wezeman MJ; Barlogie B; Epstein J
Antimyeloma efficacy of thalidomide in the SCID-hu model
16
139030591390 2002 BLOOD REVIEWS 16(4):207-215
Strasser K; Ludwig H
Thalidomide treatment in multiple myeloma
34
#LCRNCRNodes / Date / Journal / AuthorsLCSGCS
1391001391 2002 BONE MARROW TRANSPLANTATION 29:S100-S100
Mohty M; Stoppa A; Blaise D; Isnardon D; Gastaut J; Olive D; Gaugler B
Differential regulation of dendritic cell function by the Immunomodulatory drug thalidomide: implications for multiple myeloma therapy
00
1392001392 2002 BONE MARROW TRANSPLANTATION 29:S104-S104
Patriarca F; Fill C; Sperotto A; Damiani D; Zaja F; Cerno M; Fanin R
Thalidomide overcomes VAD chemoresistance and allows PBSC collection in 3 multiple myeloma patients
00
1393001393 2002 BONE MARROW TRANSPLANTATION 29:S255-S256
Dagan L; Ovadia R; Taou D; Bar L
The introduction of thalidomide (T) in BMT programs for patients with multiple myeloma (MM): encouraging results and a challenge for nursing team
00
13949191394 2002 BONE MARROW TRANSPLANTATION 29(7):577-580
Ahmad I; Islam T; Chanan-Khan A; Hahn T; Wentling D; Becker JL; McCarthy PL; Alam AR
Myeloma - Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT
67
1395001395 2002 BRITISH JOURNAL OF CANCER 86:S26-S26
Marriott JB; Clarke IA; Dredge K; Pandha H; Kristaleit H; Polychronis A; Muller GW; Stirling D; Dalgleish AG
Thalidomide analogue CDC-501 is safe and well tolerated by patients with end stage cancer and shows evidence of clinical responses and extensive immune activation
33
1396001396 2002 BRITISH JOURNAL OF CANCER 86:S42-S42
Braybrooke JP; Madhusudan S; Blann A; Wilner S; Flanagan E; Jenkins A; Echeta C; Perren T; Ganesan TS
Randomised phase two study of carboplatin versus carboplatin and thalidomide in patients with ovarian cancer, with evaluation of potential surrogate markers of angiogenesis.
00
1397001397 2002 BRITISH JOURNAL OF CANCER 86:S117-S118
Marriott JB; Clarke IA; Czajka A; Dredge K; Childs K; Man HW; Schafer P; Govinda S; Muller GW; Stirling D; Dalgleish AG
A novel subclass of thalidomide analogue with anti-solid tumour activity in which caspase dependent apoptosis is associated with altered expression of BCL-2 family proteins
00
139810361398 2002 BRITISH JOURNAL OF CANCER 87(10):1166-1172
Dredge K; Marriott JB; Macdonald CD; Man HW; Chen R; Muller GW; Stirling D; Dalgleish AG
Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects
1016
1399461399 2002 BRITISH JOURNAL OF DERMATOLOGY 146(6):1112-1113
Pouaha J; Martin S; Reichert-Penetrat S; Trechot P; Barbaud A; Schmutz JL
Thalidomide and sexual dysfunction in men
00
140012361400 2002 BRITISH JOURNAL OF HAEMATOLOGY 117(2):288-296
Elliott MA; Mesa RA; Li CY; Hook CC; Ansell SM; Levitt RM; Geyer SM; Tefferi A
Thalidomide treatment in myelofibrosis with myeloid metaplasia
1323
#LCRNCRNodes / Date / Journal / AuthorsLCSGCS
1401451401 2002 BRITISH JOURNAL OF HAEMATOLOGY 117(4):996-997
Bauduer F
Efficacy of thalidomide in the treatment of VAD-refractory plasma cell leukaemia appearing after autologous stem cell transplantation for multiple myeloma
00
1402441402 2002 BRITISH JOURNAL OF HAEMATOLOGY 118(1):347-347
Myers B; Dolan G
Analysis of durability of response to thalidomide treatment for relapsed myeloma patients
11
14038121403 2002 BRITISH JOURNAL OF HAEMATOLOGY 119(1):128-130
Wilson EA; Jobanputra S; Jackson R; Parker AN; McQuaker IG
Response to thalidomide in chemotherapy-resistant mantle cell lymphoma: a case report
13
1404351404 2002 BRITISH JOURNAL OF HAEMATOLOGY 119(1):275-275
Pitini V; Teti D; Arrigo C; Aloi G
Thalidomide treatment of relapsed multiple myeloma patients and changes in circulating VEGF and bFGF
00
1405041405 2002 BRITISH JOURNAL OF HAEMATOLOGY 119(2):576-577
Jones SG; Dolan G; Lengyel K; Myers B
Severe increase in creatinine with hypocalcaemia in thalidomide-treated myeloma patients receiving zoledronic acid infusions
03
1406671406 2002 BRITISH JOURNAL OF HAEMATOLOGY 119(3):883-884
Gonzalez-Porras JR; Gonzalez M; Garcia-Sanz R; San Miguel JF
Thalidomide in combination with cyclophosphamide and dexamethasone (ThaCyDex) is effective in soft-tissue plasmacytomas
00
1407991407 2002 BRITISH JOURNAL OF OPHTHALMOLOGY 86(11):1303-1305
Eter N; Spitznas M
DMSO mimics inhibitory effect of thalidomide on choriocapillary endothelial cell proliferation in culture
00
1408191408 2002 BRITISH JOURNAL OF OPHTHALMOLOGY 86(11):1315-1316
Shuttleworth GN; Cook SD; Ropner JE
Vanishing corneal epithelial crystals following thalidomide induced resolution of myeloma related paraproteinaemia
00
1409021409 2002 BRITISH JOURNAL OF PHARMACOLOGY 137
Paxton JW; Kestell P; Ding Q; Ching LM; Zhou S; Palmer BD; Baguley BC
Preliminary investigations into the pharmacokinetic interaction between cyclophosphamide and thalidomide in the mouse
00
1410551410 2002 BRITISH MEDICAL JOURNAL 325(7374):1245-1245
Ashby J; Tinwell H
Thalidomide is not a human mutagen
00
#LCRNCRNodes / Date / Journal / AuthorsLCSGCS
141113331411 2002 CANCER 95(4):758-765
Daliani DD; Papandreou CN; Thall PF; Wang XM; Perez C; Oliva R; Pagliaro L; Amato R
A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma
611
14126431412 2002 CANCER 95(8):1629-1636
Desai AA; Vogelzang NJ; Rini BI; Ansari R; Krauss S; Stadler WM
A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma
815
141316291413 2002 CANCER BIOLOGY & THERAPY 1(6):669-673
Ando L; Price DK; Dahut WL; Cox MC; Reed E; Figg WD
Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide
00
141410231414 2002 CANCER CHEMOTHERAPY AND PHARMACOLOGY 50(3):186-192
Ding Q; Kestell P; Baguley BC; Palmer BD; Paxton JW; Muller G; Ching LM
Potentiation of the antitumour effect of cyclophosphamide in mice by thalidomide
22
1415801181415 2002 CANCER INVESTIGATION 20(5-6):835-848
Baidas S; Tfayli A; Bhargava P
Thalidomide: An old drug with new clinical applications
13
141619511416 2002 CANCER INVESTIGATION 20(7-8):1051-1058
Jaslow R; Kaplan G; Lyons L; Michaeli J; Coleman M
Thalidomide in multiple myeloma-from the clinic to the laboratory
00
1417451417 2002 CELL SIGNALING, TRANSCRIPTION, AND TRANSLATION AS THERAPEUTIC TARGETS 973:414-418
Jin SH; Il Kim T; Han DS; Shin SK; Kim WH
Thalidomide suppresses the interleukin 1 beta-induced NF kappa B signaling pathway in colon cancer cells
13
1418001418 2002 CHEMICAL & ENGINEERING NEWS 80(40):60-60
[Anon]
Thalidomide and Frances Kelsey
00
14192181419 2002 CHEMICAL COMMUNICATIONS (19):2242-2243
Augusti DV; Augusti R; Carazza F; Cooks RG
Quantitative determination of the enantiomeric composition of thalidomide solutions by electrospray ionization tandem mass spectrometry
00
142014291420 2002 CHEST 122(1):227-232
Baughman RP; Judson MA; Teirstein AS; Moller DR; Lower EE
Thalidomide for chronic sarcoidosis
427
#LCRNCRNodes / Date / Journal / AuthorsLCSGCS
142133371421 2002 CLINICAL AND EXPERIMENTAL IMMUNOLOGY 130(1):75-84
Marriott JB; Clarke IA; Dredge K; Muller G; Stirling D; Dalgleish AG
Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells
1719
14228161422 2002 CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 20(4):S43-S44
Seyahi E; Ozdogan H; Masatlioglu S; Yazici H
Successful treatment of familial Mediterranean fever attacks with thalidomide in a colchicine resistant patient
04
1423751301423 2002 CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 20(5):709-718
Ossandon A; Cassara EAM; Priori R; Valesini G
Thalidomide: focus on its employment in rheumatologic diseases
24
142414181424 2002 CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 20(6):S158-S161
Huang F; Wei JCC; Breban M
Thalidomide in ankylosing spondylitis
01
142525541425 2002 CLINICAL CANCER RESEARCH 8(6):1964-1973
Ando Y; Fuse E; Figg WD
Thalidomide metabolism by the CYP2C subfamily
1415
1426191426 2002 CLINICAL CANCER RESEARCH 8(8):2750-2750
Go RS; Horstman AL
Correspondence re: K. Neben et al, High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. Clin. Cancer Res., 7 : 2675-2681, 2001.
00
1427061427 2002 CLINICAL CANCER RESEARCH 8(8):2751-2751
Neben K
Correspondence re: K. Neben et al, High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. Clin. Cancer Res., 7 : 2675-2681, 2001. Reply
00
142817241428 2002 CLINICAL CANCER RESEARCH 8(11):3377-3382
Neben K; Moehler T; Benner A; Kraemer A; Egerer G; Ho AD; Goldschmidt H
Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma
913
142912491429 2002 CLINICAL IMMUNOLOGY 102(3):225-236
Oliver SJ; Kikuchi T; Krueger JG; Kaplan G
Thalidomide induces granuloma differentiation in sarcoid skin lesions associated with disease improvement
48
1430001430 2002 CLINICAL IMMUNOLOGY 103(3):S95-S95
Verastegui E; Morales R; Martinez R; Barrera J
Immunological effects of thalidomide treatment of cancer patients.
00
#LCRNCRNodes / Date / Journal / AuthorsLCSGCS
1431001431 2002 CLINICAL PHARMACOLOGY & THERAPEUTICS 71(2):P83-P83
Lakhani N; Gordon S; Figg W; Dionne R
Absorption and adverse effects of topical thalidomide.
00
143257821432 2002 CRITICAL REVIEWS IN IMMUNOLOGY 22(5-6):425-437
Dredge K; Marriott JB; Dalgleish AG
Immunological effects of thalidomide and its chemical and functional analogs
02
1433581071433 2002 CROATIAN MEDICAL JOURNAL 43(3):274-285
Mujagic H; Chabner BA; Mujagic Z
Mechanisms of action and potential therapeutic uses of thalidomide
12
143433531434 2002 CURRENT OPINION IN ONCOLOGY 14(6):635-640
Raje N; Anderson KC
Thalidomide and immunomodulatory drugs as cancer therapy
814
143510261435 2002 DERMATOLOGY 204(4):365-367
Nijsten T; Meuleman L; Schroyens W; Lambert J
Thalidomide-induced morbilliform rash: Diagnosis and continuation of therapy, premedicated with methylprednisolone
00
1436661436 2002 DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT 127(15):818-818
Mensing H
New indication for thalidomide?
00
14376381437 2002 DEVELOPMENTAL DYNAMICS 225(2):186-194
Hansen JM; Gong SG; Philbert M; Harris C
Misregulation of gene expression in the redox-sensitive NF-kappa B-dependent limb outgrowth pathway by thalidomide
13
1438001438 2002 DRUG METABOLISM REVIEWS 34:148-148
Zhou SF; Li Y; Kestell P; Paxton JW
Preliminary study of thalidomide transport by the human intestinal cell line Caco-2
00
14393341439 2002 DRUG NEWS & PERSPECTIVES 15(9):604-611
Botting J
The history of thalidomide
01
14401021641440 2002 DRUGS & AGING 19(2):85-100
Zhou SF; Kestell P; Tingle MD; Paxton JW
Thalidomide in cancer treatment - A potential role in the elderly?
45
#LCRNCRNodes / Date / Journal / AuthorsLCSGCS
1441001441 2002 EUROPEAN JOURNAL OF CANCER 38:S53-S53
Villalona-Calero M; Duan W; Otterson G; Kleiber B; Hindman K; Shah M; Young D; Wu W; Kuhn J
Thalidomide modulation of Irinotecan; an NF-kB dependent effect?
00
1442001442 2002 EUROPEAN JOURNAL OF CANCER 38:S82-S82
Ng SSW; Kruger EA; Luzzio FA; Eger K; Guetschow M; Hauschildt S; Hecker T; Teubert U; Weiss M; Figg WD
In vitro antiangiogenic activity of thalidomide analogues
00
144313141443 2002 EUROPEAN JOURNAL OF DERMATOLOGY 12(1):63-65
Frances C; El Khoury S; Gompel A; Becherel PA; Chosidow O; Piette JC
Transient secondary amenorrhea in women treated by thalidomide
12
14445251444 2002 EUROPEAN JOURNAL OF HEART FAILURE 4(4):455-460
Vescovo G; Ravara B; Angelini A; Sandri M; Carraro U; Ceconi C; Libera LD
Effect of thalidomide on the skeletal muscle in experimental heart failure
12
144519361445 2002 EUROPEAN JOURNAL OF PHARMACOLOGY 453(2-3):325-334
Thiele A; Bang R; Gutschow M; Rossol M; Loos S; Eger K; Tiegs G; Hauschildt S
Cytokine modulation and suppression of liver injury by a novel analogue of thalidomide
13
14468231446 2002 EUROPEAN JOURNAL OF SURGERY 168(11):641-645
Mall JW; Schwenk W; Philipp AW; Muller JM; Pollmann C
Thalidomide given intraperitoneally reduces the number of postoperative adhesions after large bowel resection in rabbits
00
1447001447 2002 EXPERIMENTAL HEMATOLOGY 30(6):60-60
Biscardi M; Gavazzi S; Balestri F; Grossi A
Angiogenic growth factors (VEGF, TGF-b1, bFGF) and thalidomide effect in myelofibrosis with myeloid metaplasia
00
1448001448 2002 EXPERIMENTAL HEMATOLOGY 30(6):98-98
Schey S; Jones R; Raj K; Streetley M
A phase I study of an immunomodulatory thalidomide analogue (CC4047) in relapse/refractory multiple myeloma
00
1449001449 2002 EXPERIMENTAL HEMATOLOGY 30(6):98-98
Mohty M; Blaise D; Isnardon D; Olive D; Gaugler B
Differential regulation of dendritic cell function by the immunomodulatory drug thalidomide: implications for multiple myeloma therapy
00
14507181450 2002 FARMACO 57(7):551-554
Blaschke G; Meyring M; Muhlenbrock C; Chankvetadze B
Recent results of biotransformation of drugs: investigation of the in vitro biotransformation of thalidomide using a dual cyclodextrin system in capillary electrophoresis
02
#LCRNCRNodes / Date / Journal / AuthorsLCSGCS
1451001451 2002 FERTILITY AND STERILITY 77(2):S28-S28
Zhong S; Shen K; Lang J
The effects of thalidomide on interleukin-6 and vascular endothelial growth factor expression of endometrial stromal cell in vitro.
00
1452001452 2002 FERTILITY AND STERILITY 78(3):S87-S87
Scarpellini F; Sbracia M; Lecchini S; Scarpellini L
Anti-angiogenesis treatment with thalidomide in endometriosis: A pilot study.
01
1453001453 2002 GASTROENTEROLOGY 122(4):A194-A194
Bauditz J; Wedel S; Lochs H
Thalidomide for treatment of intestinal bleeding: Correlation to VEGF
11
1454001454 2002 GASTROENTEROLOGY 122(4):A395-A395
Kim JW; Kim SG; Kim HD; Kim CG; Kim BG; Kim JS; Jung HC; Song IS
Effect of DA-6034 and thalidomide on trinitrobenzene sulfonic acid-induced murine ileitis
00
1455001455 2002 GASTROENTEROLOGY 122(4):A498-A498
Sabate JM; Villarejo J; Lemann M; Bonnet J; Allez M; Modigliani R
An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease
00
145612381456 2002 GASTROENTEROLOGY 123(1):291-300
Enomoto N; Takei Y; Hirose M; Ikejima K; Miwa H; Kitamura T; Sato N
Thalidomide prevents alcoholic liver injury in rats through suppression of Kupffer cell sensitization and TNF-alpha production
314
1457001457 2002 GUT 50:A4-A4
Khan ZH; Simpson E; Cole AT; Macdonald I; Pye D; Austin A; Freeman JG
Oesophageal cancer and cachexia: The effects of thalidomide on weight loss and lean body mass in a sequential (metabolic) study
11
145813361458 2002 GUT 50(2):196-200
Bauditz J; Wedel S; Lochs H
Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease
1125
145918231459 2002 HAEMATOLOGICA 87(3):233-234
Tosi P; Cavo M
Thalidomide in multiple myeloma: state of art
34
1460471460 2002 HAEMATOLOGICA 87(3):327-328
Corso A; Lorenzi A; Orlandi E; Astori C; Mangiacavalli S; Lazzarino M
Advantages of using thalidomide for the management of patients with refractory myeloma
34
#LCRNCRNodes / Date / Journal / AuthorsLCSGCS
146113201461 2002 HAEMATOLOGICA 87(4):344-345
Ribatti D; Vacca A
Is thalidomide a true anti-angiogenic molecule in multiple myeloma?
11
146214221462 2002 HAEMATOLOGICA 87(4):345-346
[Anon]
Inside Haematologica: caution in the use of thalidomide for treatment of hematologic disorders
00
146315351463 2002 HAEMATOLOGICA 87(4):408-414
Tosi P; Zamagni E; Cellini C; Ronconi S; Patriarca F; Ballerini F; Musto P; Di Raimondo F; Ledda A; Lauria F; Masini L; Gobbi M; Vacca A; Ria R; Cangini D; Tura S; Baccarani M; Cavo M
Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma
1929
14643101464 2002 HAEMATOLOGICA 87(8):884-886
Musto P; Falcone A; Sanpaolo G; Bisceglia M; Matera R; Carella AM
Thalidomide abolishes transfusion-dependence in selected patients with myelodysplastic syndromes
11
1465181465 2002 HAUTARZT 53(2):150-150
Ochsendorf F; Kaufman R
Thalidomide in the treatment of cutaneous and systemic sarcoidosis
00
1466221466 2002 HAUTARZT 53(2):150-151
Mensing H
Thalidomide in the treatment of cutaneous and systemic sarcoidosis - Statement
00
146713151467 2002 HAUTARZT 53(11):744-748
Bohmeyer J; Achenbach A; Westenberger M; Stadler R
Thalidomide therapy of cutaneous lupus erythematosus
11
146811221468 2002 INTERNATIONAL IMMUNOPHARMACOLOGY 2(8):1143-1153
Shannon EJ; Sandoval FG
Thalidomide can costimulate or suppress CD4(+) cells' ability to incorporate [H-3]-thymidine-dependence on the primary stimulant
44
1469001469 2002 INTERNATIONAL JOURNAL OF CANCER :104-104
Hatjiharissi E; Gerotziafas G; Papaioannou M; Bakaloudi V; Tokmaktsis A; Kaloutsi V; Christakis J; Zervas K
Efficacy and tolerability of combination thalidomide-dexamethasone in multiple myeloma patients with refractory disease
00
1470001470 2002 INTERNATIONAL JOURNAL OF CANCER :336-337
Chen LT; Chao Y; Yao TJ; Huang JD; Chang JY; Chin YH; Chuang TR; Reed E; Whang-Peng J; Liu TW
Phase I and pharmacokinetic studies of oral thalidomide in advanced hepatocellular carcinoma
00
#LCRNCRNodes / Date / Journal / AuthorsLCSGCS
1471001471 2002 INTERNATIONAL JOURNAL OF CANCER :402-402
Hatjiharissi E; Gerotziafas G; Hatjileontis C; Galaktidou G; Bakaloudi V; Papaioannou M; Kaloutsi V; Kortsaris A; Christakis J; Zervas K
Study of neoangiogenesis and cytokine serum levels in patients with refractory multiple myeloma treated with thalidomide-dexamethasone
00
147227441472 2002 INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY 83(2):99-104
Arrieta O; Guevara P; Tamariz J; Rembao D; Rivera E; Sotelo J
Antiproliferative effect of thalidomide alone and combined with carmustine against C6 rat glioma
13
14737201473 2002 INTERNATIONAL JOURNAL OF HEMATOLOGY 76(4):365-369
Miller S; Sharda S; Rodrigue J; Mehta P
Thalidomide in chronic graft-versus-host disease after stem cell transplantation: Effects on quality of life
00
147419301474 2002 INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE 6(7):569-572
Fu LM; Fu-Liu CS
Thalidomide and tuberculosis
23
147511191475 2002 INVESTIGATIONAL NEW DRUGS 20(4):389-393
Minor DR; Monroe D; Damico LA; Meng G; Suryadevara U; Elias L
A phase II study of thalidomide in advanced metastatic renal cell carcinoma
710
147614281476 2002 JAPANESE JOURNAL OF CANCER RESEARCH 93(9):1029-1036
Kakimoto T; Hattori Y; Okamoto S; Sato N; Kamata T; Yamaguchi M; Morita K; Yamada T; Takayama N; Uchida H; Shimada N; Tanigawara Y; Ikeda Y
Thalidomide for the treatment of refractory multiple myeloma: Association of plasma concentrations of thalidomide and angiogenic growth factors with clinical outcome
33
14774401477 2002 JCR-JOURNAL OF CLINICAL RHEUMATOLOGY 8(5):256-259
Barthel HR; Charrier U; Kramer M; Loch C
Successful treatment of idiopathic febrile panniculitis (Weber-Christian disease) with thalidomide in a patient having failed multiple other medical therapies
00
147816341478 2002 JOURNAL OF CARDIAC FAILURE 8(5):306-314
Agoston I; Dibbs ZI; Wang F; Muller G; Zeldis JB; Mann DL; Bozkurt B
Preclinical and clinical assessment of the safety and potential efficacy of thalidomide in heart failure
23
147939671479 2002 JOURNAL OF CELLULAR AND MOLECULAR MEDICINE 6(2):160-174
Kumar S; Witzig TE; Rajkumar SV
Thalidomide as an anti-cancer agent
610
148016241480 2002 JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES 767(1):145-151
Teo SK; Chandula RS; Harden JL; Stirling DI; Thomas SD
Sensitive and rapid method for the determination of thalidomide in human plasma and semen using solid-phase extraction and liquid chromatography-tandem mass spectrometry
45
#LCRNCRNodes / Date / Journal / AuthorsLCSGCS
148110151481 2002 JOURNAL OF CLINICAL GASTROENTEROLOGY 35(2):149-150
Kane S; Stone LJ; Ehrenpreis E
Thalidomide as "salvage" therapy for patients with delayed hypersensitivity response to infliximab - A case series
35
148210191482 2002 JOURNAL OF CLINICAL MICROBIOLOGY 40(6):2302-2304
Curley MJ; Hussein SA; Hassoun PM
Disseminated herpes simplex virus and varicella zoster virus coinfection in a patient taking thalidomide for relapsed multiple myeloma
00
14836201483 2002 JOURNAL OF CLINICAL ONCOLOGY 20(1):302-306
Motzer RJ; Berg W; Ginsberg M; Russo P; Vuky J; Yu R; Bacik J; Mazumdar M
Phase II trial of thalidomide for patients with advanced renal cell carcinoma
2236
1484241484 2002 JOURNAL OF CLINICAL ONCOLOGY 20(4):1147-1149
Abramson N; Stokes PK; Luke M; Marks AR; Harris JM
Ovarian and papillary-serous peritoneal carcinoma: Pilot study with thalidomide
03
1485441485 2002 JOURNAL OF CLINICAL ONCOLOGY 20(5):1429-1430
Nathan PD; Gore ME; Eisen TG
Unexpected toxicity of combination thalidomide and interferon alfa-2a treatment in metastatic renal cell carcinoma
812
1486451486 2002 JOURNAL OF CLINICAL ONCOLOGY 20(8):2212-2212
Cany L; Fitoussi O; Boiron JM; Marit G
Tumor lysis syndrome at the beginning of thalidomide therapy for multiple myeloma
44
148720241487 2002 JOURNAL OF CLINICAL ONCOLOGY 20(11):2607-2609
Eisen T
Thalidomide in solid malignancies
612
14886261488 2002 JOURNAL OF CLINICAL ONCOLOGY 20(11):2610-2615
Hwu WJ; Krown SE; Panageas KS; Menell JH; Chapman PB; Livingston PO; Williams LJ; Quinn CJ; Houghton AN
Temozolomide plus thalidomide in patients with advanced melanoma: Results of a dose-finding trial
1222
1489111489 2002 JOURNAL OF CLINICAL ONCOLOGY 20(15):3361-3361
Hwu WJ; Krown SE; Panageas KS; Menell JH; Chapman PB; Livingston PO; Williams LJ; Quinn CJ; Houghton AN
Temozolomide plus thalidomide in patients with advanced melanoma: Results of a dose-finding trial (vol 20, pg 2610, 2002)
00
149021371490 2002 JOURNAL OF CLINICAL ONCOLOGY 20(21):4319-4323
Rajkumar SV; Hayman S; Gertz MA; Dispenzieri A; Lacy MQ; Greipp PR; Geyer S; Iturria N; Fonseca R; Lust JA; Kyle RA; Witzig TE
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma
3357
#LCRNCRNodes / Date / Journal / AuthorsLCSGCS
149110211491 2002 JOURNAL OF COMBINATORIAL CHEMISTRY 4(2):149-153
Xiao ZL; Schaefer K; Firestine S; Li PK
Solid-phase synthesis of thalidomide and its analogues
04
149213251492 2002 JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 17(2):135-139
Bariol C; Meagher AP; Vickers CR; Byrnes DJ; Edwards PD; Hing M; Wettstein AR; Field A
Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease
813
149310181493 2002 JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 17(3):233-235
Selby W
Thalidomide in inflammatory bowel disease: Too little, too soon
00
149437671494 2002 JOURNAL OF IMMUNOLOGY 168(6):2644-2651
Majumdar S; Lamothe B; Aggarwal BB
Thalidomide suppresses NF-kappa B activation induced by TNF and H2O2, but not that activated by ceramide, lipopolysaccharides, or phorbol ester
1225
149523421495 2002 JOURNAL OF IMMUNOLOGY 168(10):4914-4919
Dredge K; Marriott JB; Todryk SM; Muller GW; Chen R; Stirling DI; Dalgleish AG
Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity
1429
149613151496 2002 JOURNAL OF INFECTIOUS DISEASES 185(9):1359-1363
Wohl DA; Aweeka FT; Schmitz J; Pomerantz R; Cherng DW; Spritzler J; Fox L; Simpson D; Bell D; Holohan MK; Thomas S; Robinson W; Kaplan G; Teppler H; Natl Inst Allergy Infect Dis AIDS
Safety, tolerability, and pharmacokinetic effects of thalidomide in patients infected with human immunodeficiency virus: AIDS Clinical Trials Group 267
55
1497001497 2002 JOURNAL OF INVESTIGATIVE DERMATOLOGY 119(1):212-212
Heere-Ress E; Boehm J; Hoeller C; Thallinger C; Wolff K; Pehamberger H; Jansen B
Anti-tumor effect of thalidomide and dacarbazine in melanoma SCID mouse model
00
1498681498 2002 JOURNAL OF INVESTIGATIVE DERMATOLOGY 119(5):987-988
Gaspari A
Thalidomide neurotoxicity in dermatological patients: The next "STEP''
12
149917241499 2002 JOURNAL OF INVESTIGATIVE DERMATOLOGY 119(5):1020-1026
Bastuji-Garin S; Ochonisky S; Bouche P; Gherardi RK; Duguet C; Djerradine Z; Poli F; Revuz J; Thalidomide Neuropathy Study Grp
Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients
912
150023301500 2002 JOURNAL OF LEUKOCYTE BIOLOGY 72(5):939-945
Mohty M; Stoppa AM; Blaise D; Isnardon D; Gastaut JA; Olive D; Gaugler A
Differential regulation of dendritic cell function by the immunomodulatory drug thalidomide
26

Page 5:  1  2  3  4  5  6  7
Generated by: HistCite 2004.10.27